3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
26
Paclitaxel
22
Oxaliplatin
20
Nivolumab
16
Docetaxel
16
Capecitabine
16
Cisplatin
15
Fluorouracil
11
Cyclophosphamide
11
fludarabine
10
S 1 (combination)
10
Trastuzumab
9
Irinotecan
9
Carboplatin
8
Leucovorin
7
tislelizumab
6
aldesleukin
5
Ramucirumab
5
Interleukin-2
5
Gemcitabine
5
Drug Therapy
5
Bevacizumab
5
sintilimab
4
fludarabine phosphate
4
apatinib
4
Radiotherapy
4
Everolimus
4
regorafenib
3
olaparib
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Stomach Neoplasms
×
bempegaldesleukin
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts